Suvratoxumab

Suvratoxumab
Monoclonal antibody
Type	?
Source	Human
Target	Staphylococcus aureus alpha toxin
Clinical data
Other names	MEDI4893
ATC code	none;
Identifiers
CAS Number	1629620-18-3;
ChemSpider	none;
UNII	4L1997J4DF;
KEGG	D11124;
Chemical and physical data
Formula	C6556H10114N1730O2100S44
Molar mass	148179.68 g·mol−1

Suvratoxumab (INN;^[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.^[2]

This drug was developed by MedImmune^[3]

References

^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
^ Piscaglia M, Scaglione G, Genovese C, Borgonovo F, Brivio F, Rampichini F, et al. (August 2025). "Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials". Infectious Diseases and Therapy. 14 (8): 1619–1647. doi:10.1007/s40121-025-01195-2. PMC 12339841. PMID 40715971.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.

[World_Health_Organization_2016-1] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).

[Piscaglia_2025-2] Piscaglia M, Scaglione G, Genovese C, Borgonovo F, Brivio F, Rampichini F, et al. (August 2025). "Exploring Human Use of Monoclonal Antibodies Against Critical Bacteria: A Scoping Review of Clinical Trials". Infectious Diseases and Therapy. 14 (8): 1619–1647. doi:10.1007/s40121-025-01195-2. PMC 12339841. PMID 40715971.

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.

[1]

[2]

[3]